Literatur
Serruys PW, Chevalier B, Sotomi Y et al (2016) Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year, randomized, controlled, single-blind, multicenter trial. Lancet 388(10059):2479–2491. doi:10.1016/s0140-6736(16)32050-5
Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW, ABSORB III Investigators (2015) Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 373(20):1905–1915
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Eggebrecht gibt an, dass kein Interessenkonflikt besteht.
Rights and permissions
About this article
Cite this article
Eggebrecht, H. ABSORB III: Mehr Infarkte nach bioresorbierbarem Scaffold im Langzeitverlauf. Kardiologe 11, 250–252 (2017). https://doi.org/10.1007/s12181-017-0145-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-017-0145-1